News

The FDA has approved amifampridine (Firdapse) tablets as the first ever treatment of the rare autoimmune disorder, Lambert-Eaton myasthenic syndrome (LEMS) in adults.

The rare disease is associated with other autoimmune conditions including small cell lunger cancer, and is estimated to be prevalent in approximately 3 million people worldwide.

Progestin compound segesterone acetate, which would be combined with testosterone, is currently marketed for the use of hormonal contraception, and for the treatment of endometriosis.

The FDA has approved gilteritinib (XOSPATA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

The FDA has approved rituximab-abbs (Truxima) for the treatment of adult patients with non-Hodgkin’s lymphoma. This indication stands as the first FDA-approved biosimilar for the rare blood cancer.

A new study found the annual top-50 ranking is a reliable indicator of cardiovascular disease mortality and patient satisfaction.

Investigators in Denmark found that both current and ex-smokers have an increased risk of developing myeloproliferative neoplasms.

The 4th generation VITROS HIV Combo test has been approved for use with the VITROS ECi/ECiQ Immunodiagnostic System.

Mayo Clinic investigators found young patients with myeloproliferative neoplasms who are under age 40 are a steadily growing population and seem to have longer survival than their older counterparts.

Investigators indicated areas of potential improvement for the treatment of new or recurrent C difficile infection.

The risk of death among formerly incarcerated people with HIV was much lower among those who had health insurance and received case management after release.

A small study shows it’s safe to give immunotherapy to patients with HIV who also have cancer.

The FDA has granted an accelerated approval to larotrectinib (Vitrakvi, Bayer and Loxo Oncology, Inc) for the treatment of pediatric and adult solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusion.

What could have been uncovered is further evidence for a progressive-onset MS phenotype characterized by acute episodic inflammatory changes.

HIV-2 is not less life-threatening than HIV-1, according to new research. The only difference is in the timing.

Old researchers shows children with asthma who experience chronic stress have a heightened inflammatory response profile that puts them at risk for asthma exacerbations.

The ACTPen was approved on the basis of a pair of clinical trials presented at the 2018 American Society for Clinical Pharmacology & Therapeutics Annual Meeting.

Topline data shows that the diabetes medication is non-inferior to placebo with regard to a composite outcome of major adverse cardiovascular events.

The recently approved phenylketonuria (PKU) drug, pegvaliase, is helping patients experience less disease burden—and drastically in some cases.

New research warns that the mechanisms behind HIV latency vary significantly in the blood and the gut.

Prevalence of hypertension in HIV-positive persons is not attributed to antiretroviral drug treatment in largest adverse event surveillance study.

The septic shock therapy was approved by the FDA last December. How has it fared in its first year of real-world clinical use?

A combination of raltegravir plus boosted protease inhibitor was found equal to triple antiretroviral combination for HIV even in patients with previous treatment failure.

Investigators found that among adolescents that began as never users, e-cigarette users were more likely to become experimental, infrequent or frequent combustible cigarette users.

Research into epilepsy and HRV has been ongoing for more than 30 years, so why hasn’t it been integrated into clinical practice?

The drug is approved as a treatment for adult patients with newly-diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

Young people who inject drugs tell why they do not—or cannot— receive treatment for hepatitis C virus infection.

Severe influenza was found to be an independent risk factor for invasive aspergillosis in the largest study conducted on the concurrent pulmonary infections.

According to the FDA, patients who stop the therapy are at a severe risk of symptoms worsening than previously to them even starting therapy.

Emapalumab-lzsg was approved by the FDA for the treatment of primary hemophagocytic lymphohistiocytosis in pediatric and adult patients with refractory, recurrent, or progressive disease, or intolerance to conventional therapy.